THZ531
目录号 : GC16420An inhibitor of Cdk12 and Cdk13
Cas No.:1702809-17-3
Sample solution is provided at 25 µL, 10mM.
THZ531 is a first-in-class CDK12 and CDK13 covalent inhibitor with IC50 values of 158 nM and 69 nM, respectively [1].
Complexes containing CDK12 and CDK13 regulate transcriptional elongation as well as processes, including mRNA splicing and 3’-end RNA processing. Loss of CDK12 and CDK13, or of their cofactor cyclin K, impedes both Pol II processivity and RNA processing [1].
THZ531 is an irreversible CDK12 and CDK13 covalent inhibitor. THZ531 potently inhibited CDK12 and CDK13 with IC50 values of 158 nM and 69 nM, whereas inhibition of CDK7 and CDK9 was more than 50-fold weaker, with IC50s of 8.5 μM and 10.5 μM, respectively. In Jurkat cells, THZ531 irreversibly reduced cell proliferation with IC50 of 50 nM. THZ531 induced apoptosis in a dose- and time-dependent way. THZ531 also reduced Pol II C-terminal domain (CTD) Ser2 phosphorylation, a mark of active transcriptional elongation, resulted in the loss of key super-enhancer-associated transcription factor genes and DNA damage response (DDR) genes expression [1].
Reference:
1.Zhang T, Kwiatkowski N, Olson CM, et al. Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nat Chem Biol. 2016 Oct;12(10):876-84.
Kinase experiment [1]: | |
Binding assays |
Radioactive kinase activity measurements were performed at a concentration of 0.2 μM CDK–cyclin complex. Typically, 35 μl reaction volumes of 0.2 μM active kinase were equilibrated in kinase buffer (40 mM Hepes (pH 7.6)), 34 mM NaCl, 34 mM KCl, 10 mM MgCl2, 5% glycerol, and 1× PhosSTOP. Cold ATP to a final concentration of 200 μM and 3 μCi [γ-32P]ATP and 50 μM of a substrate peptide containing five phosphorylation sites were added and the reaction mixture incubated for 30 min at 30 °C at 350 rpm in a thermomixer. Reactions were stopped by adding EDTA to a final concentration of 50 mM. Aliquots of 15 μl each were spotted onto paper squares using the Optitran BA-S85 reinforced membrane. Paper squares were washed three times for 5 min with 0.75% (v/v) phosphoric acid, with at least 5 ml washing solution per paper. Radioactivity was counted in a Beckman Scintillation Counter (Beckman Coulter) for 1 min. Compounds THZ531 was added at varying concentrations to 0.2 μM CDK–cyclin complex and incubated for varying times from 1 to 540 min at 30 °C and 350 rpm before ATP and substrate were added to the reaction mix. |
Cell experiment [1]: | |
Cell lines |
Jurkat cells |
Preparation method |
This compound is soluble in DMSO. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
Reacting condition |
50-1200 nM, 6 h |
Applications |
THZ531 treatment led to a dramatic and irreversible decrease in Jurkat cell proliferation with an IC50 of 50 nM. Treatment with escalating doses of THZ531 displayed a dose- and time-dependent increase in the number of cells exhibiting sub-G1 content. Higher doses of THZ531 led to a pronounced annexin V signal, with 30–40% annexin-V-stained cells by 72 h. THZ531 selectively reduced Ser2 phosphorylation levels without appreciable effect on CTD pSer5 or pSer7 levels. Treatment with 50 nM THZ531 resulted in the loss of expression of a small subset of genes. |
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: [1]. Zhang T, Kwiatkowski N, Olson C M, et al. Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors[J]. Nature chemical biology, 2016. |
Cas No. | 1702809-17-3 | SDF | |
化学名 | (R,E)-N-(4-(3-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)piperidine-1-carbonyl)phenyl)-4-(dimethylamino)but-2-enamide | ||
Canonical SMILES | ClC1=CN=C(N[C@H]2CN(C(C3=CC=C(NC(/C=C/CN(C)C)=O)C=C3)=O)CCC2)N=C1C4=CNC5=C4C=CC=C5 | ||
分子式 | C30H32ClN7O2 | 分子量 | 558.07 |
溶解度 | ≥ 55.8mg/mL in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.7919 mL | 8.9594 mL | 17.9189 mL |
5 mM | 0.3584 mL | 1.7919 mL | 3.5838 mL |
10 mM | 0.1792 mL | 0.8959 mL | 1.7919 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet